MLF2 Negatively Regulates P53 and Promotes Colorectal Carcinogenesis
Advanced Science · 2023
DOI: 10.1002/advs.202303336 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Debao Fang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology o…. Hauptthemen laut MEDLINE: Tumor Suppressor Protein p53, Colorectal Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of China, National Natural Science Foundation of China, Center for Advanced Interdisciplinary Science and Biomedicine of IHM.
Abstract (Originalsprache)
Inactivation of the p53 pathway is linked to a variety of human cancers. As a critical component of the p53 pathway, ubiquitin‐specific protease 7 (USP7) acts as a deubiquitinase for both p53 and its ubiquitin E3 ligase mouse double minute 2 homolog. Here, myeloid leukemia factor 2 (MLF2) is reported as a new negative regulator of p53. MLF2 interacts with both p53 and USP7. Via these interactions, MLF2 inhibits the binding of USP7 to p53 and antagonizes USP7‐mediated deubiquitination of p53, thereby leading to p53 destabilization. Functionally, MLF2 plays an oncogenic role in colorectal cancer, at least partially, via the negative regulation of p53. Clinically, MLF2 is elevated in colorectal cancer and its high expression is associated with poor prognosis in patients with colorectal cancer. In wild‐type‐p53‐containing colorectal cancer, MLF2 and p53 expressions are inversely correlated. These findings establish MLF2 as an important suppressor of p53 function. The study also reveals a critical role for the MLF2–p53 axis in promoting colorectal carcinogenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Thoracic Surgery, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230001, China.
- The CAS Key Laboratory of Innate Immunity and Chronic Disease, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.
- Department of General Surgery, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, 230022, China.
- Center for Advanced Interdisciplinary Science and Biomedicine of IHM, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, 230027, China.
ORCID-Profile: Kailiang Zhao
Förderung
- Ministry of Science and Technology of China
- National Natural Science Foundation of China
- Center for Advanced Interdisciplinary Science and Biomedicine of IHM
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Fang, D., Hu, H., Zhao, K., Xu, A., Yu, C., Zhu, Y., Yu, N., Yao, B., Tang, S., Wu, X., & Mei, Y. (2023). MLF2 Negatively Regulates P53 and Promotes Colorectal Carcinogenesis. Advanced Science. https://doi.org/10.1002/advs.202303336
Vancouver
Fang D, Hu H, Zhao K, Xu A, Yu C, Zhu Y, et al. MLF2 Negatively Regulates P53 and Promotes Colorectal Carcinogenesis. Advanced Science. 2023. doi:10.1002/advs.202303336
BibTeX
@article{Fang2023,
author = {Fang, Debao and Hu, Hao and Zhao, Kailiang and Xu, Aman and Yu, Changjun and Zhu, Yong and Yu, Ning and Yao, Bo and Tang, Suyun and Wu, Xianning and Mei, Yide},
title = {MLF2 Negatively Regulates P53 and Promotes Colorectal Carcinogenesis},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202303336}
}
EUVIMED